How to monitor treatment response and evaluate efficacy of Mobotinib

Mobocertinib (also known as Mobocertinib) is an oral tyrosine kinase inhibitor (TKI), specifically used to treat EGFR exon 20 insertion mutations (EGFR Exon20ins)-positive non-small cell lung cancer (NSCLC) patients. Since this mutation type has poor efficacy against traditional EGFR-TKIs, the emergence of mobotinib provides a new treatment option for these patients. During treatment with mobotinib, efficacy monitoring and response evaluation are particularly important, which can help doctors determine whether the drug response is ideal, whether the treatment plan needs to be adjusted, and discover potential side effects in a timely manner.

1. Basic assessment and preparation before treatment

Before initiating treatment with mobotinib, a series of baseline examinations should be performed. The most critical thing is molecular testing, which requires high-throughput sequencing (NGS) or PCR to determine whether the patient has an EGFR exon 20 insertion mutation. This is a prerequisite for the use of mobotinib.

In addition, a comprehensive imaging evaluation is required. Commonly used methods include chest CT, whole body PET-CT or MRI, etc., to understand the primary site, size, metastasis and total amount of lesions of the tumor. This baseline data will serve as a reference for subsequent comparisons of efficacy.

The patient's liver and kidney function, electrocardiogram, electrolyte levels, blood routine and other routine items also need to be evaluated to rule out the risk of serious organic diseases and provide basic data for the management of adverse reactions during subsequent treatment.

2. Imaging evaluation: the core method for judging therapeutic efficacy

During the treatment of mobotinib, the most important tool for efficacy evaluation is still imaging examination. FollowRECIST 1.1Standards (Solid Tumor Response Evaluation Standards), it is usually recommended to conduct a CT scan or MRI review every 6～8 weeks to judge the effect of the drug by comparing changes in the size of the lesions.

If the tumor shrinks≥30%, it can be evaluated as "partial response (PR)";

If the tumor disappears completely"complete response (CR)";

If the lesion is stable (the change does not exceed ±20%), it is "stable disease (SD)";

If the lesions increase or new lesions appear, the evaluation is"disease progression (PD)".

Continuous imaging monitoring can help doctors promptly identify whether tumors are sensitive to mobotinib and decide whether to continue this treatment.

3. The auxiliary value of tumor markers and liquid biopsy

Although imaging is still the gold standard for solid tumors, monitoring of tumor markers and circulating tumor DNA (ctDNA) in the blood is also gradually being used in clinical practice. For some patients with non-small cell lung cancer, dynamic changes in indicators such as CEA and CYFRA21-1 can be monitored as an auxiliary judgment for treatment response.

Liquid biopsies (such as testing the EGFR mutation copy number in the blood) can detect resistance signals early in some cases. For example, if the frequency of EGFR 20ins mutations in ctDNA gradually increases before the lesions have not significantly enlarged, it may indicate that the tumor load is increasing or that drug-resistant clones have emerged. Such means provide a time window for early intervention.

4. Monitoring and management of adverse reactions: the other side of efficacy judgment

In addition to tumor shrinkage, adverse reactions during treatment are also an important part of the evaluation. The most common side effects of Mobotinib include diarrhea, rash, stomatitis, decreased appetite, and ECG changes such as prolongation of QT interval. Therefore, the following monitoring should be carried out regularly during treatment:

Electrolytes (especially potassium and magnesium) and ECG: PreventQT prolongation-related arrhythmias;

Liver and kidney function: Especially for elderly patients or patients with underlying diseases, drug-induced abnormal liver function should be prevented;

Quality of life and patient complaints: Although persistent severe diarrhea or skin problems do not directly reflect the efficacy, they affect patient compliance and may indirectly affect treatment continuity.

When serious adverse reactions occur during treatment, the dose may need to be adjusted or the drug temporarily discontinued, and auxiliary treatments such as antidiarrheal drugs and skin protectants may be added as appropriate.

5. Integrated analysis of long-term follow-up and efficacy

After continuous treatment for more than 3~6 months, it is necessary to comprehensively judge whether to continue the drug based on imaging, ctDNA, tumor markers, adverse reactions, patient symptoms and other indicators. Although some patients did not meet RECIST's "remission" criteria, their lesions shrank significantly, their symptoms improved, and their quality of life improved. This "clinical benefit" is also an important criterion for judging efficacy.

Once imaging shows tumor recurrence or progression, further tissue or liquid biopsy can be considered to explore the resistance mechanism, such as whether there are secondary mutations of EGFR, amplification of MET, changes in HER2, etc. Such information is important for deciding whether to change or combine medications.

6. Patient management and individualized strategies

The evaluation of the efficacy of mobotinib is not only about image changes and numerical indicators, but more importantly, whether it prolongs the patient's survival time and improves the quality of life. Therefore, doctors should develop individualized treatment and evaluation plans based on each patient's physical condition, mental endurance, financial burden and other factors. Some patients have no obvious short-term effects, but have good long-term control and are worthy of continued treatment.

In summary, the evaluation of the efficacy of Mobotinib is a systematic and dynamic process that requires a combination of imaging examinations, ctDNA analysis, biomarker monitoring, and adverse reaction management. Through a scientific and continuous evaluation mechanism, it not only helps to judge the efficacy of drugs, but also detects drug resistance or side effects in a timely manner, thereby optimizing treatment plans, extending patient survival time, and improving quality of life. For patients with EGFR Exon20insertion mutation-positive lung cancer, correct efficacy monitoring methods are the key to achieving long-term benefits.

References：https://en.wikipedia.org/wiki/Mobocertinib